Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) and Mannatech (NASDAQ:MTEX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
Valuation & Earnings
This table compares Crinetics Pharmaceuticals and Mannatech”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crinetics Pharmaceuticals | $7.70 million | 479.68 | -$465.32 million | ($5.13) | -6.83 |
| Mannatech | $108.04 million | 0.09 | -$15.21 million | ($6.71) | -0.78 |
Profitability
This table compares Crinetics Pharmaceuticals and Mannatech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crinetics Pharmaceuticals | -2,747.18% | -43.96% | -39.61% |
| Mannatech | -11.97% | -2,383.34% | -40.24% |
Insider and Institutional Ownership
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Crinetics Pharmaceuticals and Mannatech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crinetics Pharmaceuticals | 1 | 0 | 8 | 1 | 2.90 |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
Crinetics Pharmaceuticals presently has a consensus price target of $76.13, indicating a potential upside of 117.31%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Mannatech.
Summary
Crinetics Pharmaceuticals beats Mannatech on 9 of the 15 factors compared between the two stocks.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
